EGFR and non-small cell lung carcinoma: Furthermore, recent clinical trials indicated that the combination of anti-angiogenic drugs (such as bevacizumab or anlotinib) with chemotherapy, epidermal growth factor receptor (EGFR)-TKIs targeted therapy, or immunotherapy prolonged the PFS and OS of NSCLC patients [14–17].